These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22178131)

  • 1. Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition.
    Lee MS; Kim HP; Kim TY; Lee JW
    Biochim Biophys Acta; 2012 Feb; 1823(2):514-23. PubMed ID: 22178131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
    Choi J; Kang M; Nam SH; Lee GH; Kim HJ; Ryu J; Cheong JG; Jung JW; Kim TY; Lee HY; Lee JW
    Lung Cancer; 2015 Oct; 90(1):22-31. PubMed ID: 26190015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
    Zhao BX; Wang J; Song B; Wei H; Lv WP; Tian LM; Li M; Lv S
    Mol Med Rep; 2015 Apr; 11(4):2767-74. PubMed ID: 25483995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between TGFβ1 and EGFR signalling pathways induces TM4SF5 expression and epithelial-mesenchymal transition.
    Kang M; Choi S; Jeong SJ; Lee SA; Kwak TK; Kim H; Jung O; Lee MS; Ko Y; Ryu J; Choi YJ; Jeong D; Lee HJ; Ye SK; Kim SH; Lee JW
    Biochem J; 2012 May; 443(3):691-700. PubMed ID: 22292774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNK signaling activity regulates cell-cell adhesions via TM4SF5-mediated p27(Kip1) phosphorylation.
    Kim H; Jung O; Kang M; Lee MS; Jeong D; Ryu J; Ko Y; Choi YJ; Lee JW
    Cancer Lett; 2012 Jan; 314(2):198-205. PubMed ID: 22014979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TM4SF5 accelerates G1/S phase progression via cytosolic p27Kip1 expression and RhoA activity.
    Kim H; Kang M; Lee SA; Kwak TK; Jung O; Lee HJ; Kim SH; Lee JW
    Biochim Biophys Acta; 2010 Aug; 1803(8):975-82. PubMed ID: 20399237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
    J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
    J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
    Ju L; Zhou C
    Cancer Biomark; 2013; 13(5):329-36. PubMed ID: 24440972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
    Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
    Song J; Zhong R; Huang H; Zhang Z; Ding D; Yan H; Sun E; Jia X
    Nutr Cancer; 2014; 66(4):682-9. PubMed ID: 24738693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
    Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
    Lee AF; Chen MC; Chen CJ; Yang CJ; Huang MS; Liu YP
    PLoS One; 2017; 12(7):e0180383. PubMed ID: 28683123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.